Lexicon Pharmaceuticals, Inc. (LXRX) Director Public Equities L.P. Invus Acquires 29,747 Shares of Stock

Share on StockTwits

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Director Public Equities L.P. Invus bought 29,747 shares of the company’s stock in a transaction that occurred on Friday, June 8th. The shares were acquired at an average cost of $12.89 per share, with a total value of $383,438.83. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Public Equities L.P. Invus also recently made the following trade(s):

  • On Monday, June 11th, Public Equities L.P. Invus bought 98,626 shares of Lexicon Pharmaceuticals stock. The shares were acquired at an average cost of $12.75 per share, with a total value of $1,257,481.50.
  • On Wednesday, June 6th, Public Equities L.P. Invus bought 95,079 shares of Lexicon Pharmaceuticals stock. The shares were acquired at an average cost of $12.58 per share, with a total value of $1,196,093.82.
  • On Friday, June 1st, Public Equities L.P. Invus acquired 147,339 shares of Lexicon Pharmaceuticals stock. The stock was purchased at an average cost of $12.22 per share, with a total value of $1,800,482.58.
  • On Monday, June 4th, Public Equities L.P. Invus acquired 416,481 shares of Lexicon Pharmaceuticals stock. The stock was purchased at an average cost of $12.01 per share, with a total value of $5,001,936.81.
  • On Friday, May 25th, Public Equities L.P. Invus acquired 138,700 shares of Lexicon Pharmaceuticals stock. The stock was purchased at an average cost of $9.62 per share, with a total value of $1,334,294.00.
  • On Wednesday, May 30th, Public Equities L.P. Invus acquired 433,378 shares of Lexicon Pharmaceuticals stock. The stock was purchased at an average cost of $9.94 per share, with a total value of $4,307,777.32.

Shares of Lexicon Pharmaceuticals opened at $12.84 on Wednesday, according to MarketBeat. Lexicon Pharmaceuticals, Inc. has a 12-month low of $7.67 and a 12-month high of $18.00. The firm has a market cap of $1.35 billion, a P/E ratio of -10.11 and a beta of 0.48. The company has a current ratio of 2.72, a quick ratio of 2.70 and a debt-to-equity ratio of 8.85.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings data on Thursday, May 3rd. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.43) by $0.03. Lexicon Pharmaceuticals had a negative return on equity of 213.32% and a negative net margin of 140.09%. The firm had revenue of $25.21 million for the quarter, compared to analysts’ expectations of $25.30 million. During the same period last year, the business posted ($0.33) earnings per share. The firm’s revenue for the quarter was up 37.8% on a year-over-year basis. analysts predict that Lexicon Pharmaceuticals, Inc. will post -1.33 EPS for the current fiscal year.

LXRX has been the subject of several recent research reports. Citigroup lowered their price objective on shares of Lexicon Pharmaceuticals from $28.00 to $27.00 and set a “buy” rating for the company in a research report on Friday, May 4th. Stifel Nicolaus lowered their price objective on shares of Lexicon Pharmaceuticals from $25.00 to $24.00 and set a “buy” rating for the company in a research report on Friday, May 4th. BidaskClub raised shares of Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, May 17th. Zacks Investment Research upgraded Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, February 13th. Finally, Needham & Company LLC cut Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, February 23rd. Two research analysts have rated the stock with a sell rating, three have given a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $24.40.

Hedge funds have recently bought and sold shares of the business. Jump Trading LLC bought a new stake in Lexicon Pharmaceuticals in the fourth quarter valued at $104,000. Two Sigma Advisers LP bought a new stake in Lexicon Pharmaceuticals in the fourth quarter valued at $104,000. Quantitative Systematic Strategies LLC bought a new stake in Lexicon Pharmaceuticals in the fourth quarter valued at $117,000. Aperio Group LLC bought a new stake in Lexicon Pharmaceuticals in the fourth quarter valued at $127,000. Finally, Teacher Retirement System of Texas bought a new stake in Lexicon Pharmaceuticals in the fourth quarter valued at $161,000.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Insider Buying and Selling by Quarter for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Insider Buying: Synovus Financial Corp.  Director Buys $250,000.00 in Stock
Insider Buying: Synovus Financial Corp. Director Buys $250,000.00 in Stock
Evergy  Price Target Increased to $57.00 by Analysts at UBS Group
Evergy Price Target Increased to $57.00 by Analysts at UBS Group
Leggett & Platt  Raised to Hold at Zacks Investment Research
Leggett & Platt Raised to Hold at Zacks Investment Research
PRGX Global  Stock Rating Lowered by ValuEngine
PRGX Global Stock Rating Lowered by ValuEngine
Fidelity Southern  Upgraded to Buy by ValuEngine
Fidelity Southern Upgraded to Buy by ValuEngine
Hi-Crush Partners  Upgraded to Hold by ValuEngine
Hi-Crush Partners Upgraded to Hold by ValuEngine


Leave a Reply

 
© 2006-2018 Zolmax.